Prelude Therapeutics PRLD
NASDAQ PRLD
$3.89 -0.07 (-1.72%)
As of: Sep 30, 2026 · 9:41 AM EDT

Prelude Therapeutics (PRLD) EBT Margin (2024 - 2026)

Updated

Prelude Therapeutics' EBT Margin was -270.93% in Q2 2026, up 38.61 percentage points from the prior quarter.

Analysis

Prelude Therapeutics (PRLD) EBT Margin (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, Prelude Therapeutics' EBT Margin was -300.56% through Jun 30, 2026, up 1628.11 percentage points year-over-year; for FY2025, it came in at -861.33%, up 1134.58 percentage points from FY2024.

  • In earlier years, EBT Margin was -1995.91% in FY2024.
  • Per Business Quant data, PRLD's EBT Margin in the three quarters before Q2 2026 was -309.54% (Q1 2026), -307.59% (Q4 2025) and -314.12% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 26.66%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 25.18%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -4.11%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 29.63%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 18.19%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 27.53%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -131.41%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -4.34%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 41.75%
10 Prelude Therapeutics 312.03 Mn -285.27 Mn - -270.93%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -270.93%
Mar 31, 2026 -309.54%
Dec 31, 2025 -307.59%
Sep 30, 2025 -314.12%
Dec 31, 2024 -845.78%
Sep 30, 2024 -1,145.87%
API Access

Prelude Therapeutics EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=PRLD&period=max&api_key=YOUR_API_KEY